A Phase IIb Randomized Controlled Trial of the TLPLDC Vaccine as Adjuvant Therapy After Surgical Resection of Stage III/IV Melanoma: A Primary Analysis

BACKGROUND: Melanoma therapy has changed dramatically over the last decade with improvements in immunotherapy, yet many patients do not respond to current therapies. This novel vaccine strategy may prime a patient’s immune system against their tumor and work synergistically with immunotherapy agains...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς: Vreeland, Timothy J., Clifton, Guy T., Hale, Diane F., Chick, Robert C., Hickerson, Annelies T., Cindass, Jessica L., Adams, Alexandra M., Bohan, Phillip M. Kemp, Andtbacka, Robert H. I., Berger, Adam C., Jakub, James W., Sussman, Jeffrey J., Terando, Alicia M., Wagner, Thomas, Peoples, George E., Faries, Mark B.
Μορφή: Online Άρθρο Κείμενο
Γλώσσα:English
Έκδοση: Springer International Publishing 2021
Θέματα:
Melanoma
Διαθέσιμο Online:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7914039/
https://www.ncbi.nlm.nih.gov/pubmed/33641012
http://dx.doi.org/10.1245/s10434-021-09709-1

Διαδίκτυο

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7914039/
https://www.ncbi.nlm.nih.gov/pubmed/33641012
http://dx.doi.org/10.1245/s10434-021-09709-1

Παρόμοια τεκμήρια